Focused On-demand Library for Probable ATP-dependent RNA helicase DDX31

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9H8H2

UPID:

DDX31_HUMAN

Alternative names:

DEAD box protein 31; Helicain

Alternative UPACC:

Q9H8H2; Q5K6N2; Q5K6N3; Q5K6N4; Q5VZJ4; Q5VZJ9; Q96E91; Q96NY2; Q96SX5; Q9H5K6

Background:

The Probable ATP-dependent RNA helicase DDX31, also known as DEAD box protein 31 and Helicain, plays a crucial role in ribosome biogenesis and the regulation of TP53/p53 through its interaction with NPM1. This protein's involvement in critical cellular processes highlights its importance in maintaining cellular function and integrity.

Therapeutic significance:

Understanding the role of Probable ATP-dependent RNA helicase DDX31 could open doors to potential therapeutic strategies. Its pivotal role in ribosome biogenesis and TP53/p53 regulation makes it a promising target for drug discovery, aiming to harness its functions for therapeutic benefits.